vidarabine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
arabinofuranosyl derivatives 2818 5536-17-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • vidarabine anhydrous
  • vidarabine
  • adenine arabinoside
  • araadenosine
  • arabinosyladenine
  • vidarabin
A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.
  • Molecular weight: 267.25
  • Formula: C10H13N5O4
  • CLOGP: -1.36
  • LIPINSKI: 0
  • HAC: 9
  • HDO: 4
  • TPSA: 139.54
  • ALOGS: -1.28
  • ROTB: 2
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.70 g P

ADMET properties:

PropertyValueReference
BA (Bioavailability) 0 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -0.700 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 28.119 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 1.742 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.722 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 86.070 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 90.970 % High 1
herg hERG pIC50 3.626 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.148 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.350 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 75.040 % High 1
kinase-safety-class ACVR2B,AURKA,AXL,BRAF,CAMK2D,CDK5,CDK9,CLK2,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,IRAK1,ITK,MAP2K6,MAP3K21,MAPK7,NTRK1,NTRK2,PDK1,PDK2,PDK4,PIK3CD,PRKDC,SIK2 27
kinase-selectivity-class MAP2K6,MAP3K21 2
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 4.753 High 1
mh-clint Mouse hepatocyte intrinsic clearance 1.045 High 1
mppb Mouse plasma protein binding (% unbound) 92.220 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 2.636 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pld-class Phospholipidosis risk class (1 = positive, 0 = negative) 0 Moderate 0.68
pppb Pig plasma protein binding (% unbound) 89.910 % High 1
rh-clint Rat hepatocyte intrinsic clearance 1.945 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 94.770 % High 1
rppb Rat plasma protein binding (% unbound) 89.070 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 864.968 uM High 1

Approvals:

DateAgencyCompanyOrphan
Nov. 26, 1976 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J05AB03 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIVIRALS FOR SYSTEMIC USE
DIRECT ACTING ANTIVIRALS
Nucleosides and nucleotides excl. reverse transcriptase inhibitors
ATC S01AD06 SENSORY ORGANS
OPHTHALMOLOGICALS
ANTIINFECTIVES
Antivirals
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000963 Antimetabolites
MeSH PA D000998 Antiviral Agents
CHEBI has role CHEBI:22587 antiviral agent
CHEBI has role CHEBI:25605 nucleoside antibiotic
CHEBI has role CHEBI:35610 antineoplastic agent
CHEBI has role CHEBI:66981 ophthalmology drug
CHEBI has role CHEBI:76969 bacterial metabolite

Related Drugs by ATC class:

J05AB Nucleosides and nucleotides excl. reverse transcriptase inhibitors 11 drugs
acyclovirbrivudinecidofovirfamciclovirgancicloviridoxuridinemolnupiravirpenciclovirremdesivirvalaciclovirvalganciclovir
S01AD Antivirals 6 drugs
acyclovirfamciclovirfomivirsengancicloviridoxuridinetrifluridine

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Herpes simplex keratitis indication 9389005
Herpes simplex dendritic keratitis indication 29943008




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 11.67 acidic
pKa2 12.33 acidic
pKa3 13.34 acidic
pKa4 3.95 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Deoxycytidine kinase Kinase WOMBAT-PK
DNA polymerase alpha catalytic subunit Enzyme WOMBAT-PK
Ribonucleoside-diphosphate reductase large subunit Enzyme WOMBAT-PK
Ribonucleoside-diphosphate reductase subunit M2 Enzyme WOMBAT-PK
Deoxyguanosine kinase, mitochondrial Kinase WOMBAT-PK
Ribose-phosphate pyrophosphokinase 1 Kinase WOMBAT-PK
Dipeptidyl peptidase 4 Enzyme IC50 7.21 CHEMBL
DNA polymerase catalytic subunit Enzyme INHIBITOR CHEMBL CHEMBL
Adenylate cyclase type V Enzyme IC50 4.09 CHEMBL
Adenosylhomocysteinase Enzyme Ki 4.52 CHEMBL

External reference:

IDSource
4018650 VUID
N0000146963 NUI
D00406 KEGG_DRUG
4018650 VANDF
C0042646 UMLSCUI
CHEBI:45327 CHEBI
CHEMBL1090 ChEMBL_ID
DB00194 DRUGBANK_ID
D014740 MESH_DESCRIPTOR_UI
21704 PUBCHEM_CID
4806 IUPHAR_LIGAND_ID
FA2DM6879K UNII
11194 RXNORM
5673 MMSL
003014 NDDF
37306000 SNOMEDCT_US
373759007 SNOMEDCT_US
RAB PDB_CHEM_ID
2842 INN_ID
24356-66-9 SECONDARY_CAS_RN

Pharmaceutical products:

None